Tebao Bio announced that the company's product Pei Jin (generic name: Topefilgrastim injection) has obtained the "Notice of Approval for Drug Clinical Trial" approved and issued by the National Medical Products Administration for the new indication "suitable for reducing the incidence of preeclampsia". Pei Jin is a long-acting human granulocyte stimulating factor independently developed by the company. It was approved for marketing on June 30, 2023. It is suitable for patients with non-myeloid malignant tumors who are receiving myelosuppressive anticancer drugs that are prone to cause febrile neutropenia. It reduces the incidence of infection manifested by febrile neutropenia. Pei Jin uses a 40kD Y-branched polyethylene glycol (PEG) molecule to modify the human granulocyte stimulating factor, stimulates the differentiation of bone marrow hematopoietic stem cells into granulocytes, promotes granulocyte proliferation, maturation and release, and restores the number of peripheral blood neutrophils to reduce the incidence of infection in cancer patients after chemotherapy.